Balancing Blood Sugar and Brain Power as An Anti-Diabetic Drugs Classification and Basal Ganglia Function Study ...

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION ...

Researchers conducted a concept analysis of processing speed in relation to the cognitive function of patients with cancer.

FDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS Arun Swaminathan, Chief ...

It has beaten Beverly Hills as America's priciest neighborhood and billionaires are lining up to grab a waterfront home where ...

ConspectusConducting polymers (CPs), distinguished by their unique combination of electrical conductivity and optical properties, have garnered significant attention since their discovery. Owing to ...

FY 2025 Earnings Conference Call August 21, 2025 7:00 PM ETCompany ParticipantsBradley John O'Connor - CEO, MD ...

Oragenics, Inc. (NYSE American: OGEN), a pioneering biotechnology company striving to develop brain-targeted therapeutics through proprietary intranasal delivery technology, today shared key strategic ...

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the decision to discontinue the ORION program of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, ...

SeeMe, a computer vision tool tested by Stony Brook University researchers, was able to detect low-amplitude, voluntary ...